Traws Pharma

TRAW · NASDAQ

$0.3767+$0.0102 (+2.78%)TodayMarket closed ·
Prev close $0.3665

Latest news

  • News

    12 Health Care Stocks Moving In Monday's After-Market Session

  • NewsAvi Kapoor

    Why INLIF Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket

  • Press releaseGlobe Newswire

    Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights

  • Press releaseGlobe Newswire

    Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program

  • NewsVandana Singh

    Traws Pharma Stock Falls As UK Regulator Delays Key Flu Study

  • Press releaseGlobe Newswire

    Traws Pharma Provides Regulatory Update on Influenza Program

  • News

    Traws Pharma Announces Advancement Of Its Novel Proprietary Broad-Spectrum Combination Anti-Viral Agent With Potential Utility Against Hantavirus, Ebola and Lassa

  • Press releaseGlobe Newswire

    Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks

  • News

    Earnings Scheduled For May 15, 2026

  • Press releaseGlobe Newswire

    Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results

  • NewsSnigdha Gairola

    Chuck Schumer Blasts Trump, Elon Musk For Firing CDC And Port Health Workers As Hantavirus Scare Grips The World

  • News

    12 Health Care Stocks Moving In Friday's Intraday Session

  • NewsVandana Singh

    Traws Pharma Gains After Hantavirus Drug Development Update Amid Cruise Ship Outbreak

  • News

    12 Health Care Stocks Moving In Friday's Pre-Market Session

  • Press releaseGlobe Newswire

    Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections

  • News

    12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • Press releaseGlobe Newswire

    Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights

  • News

    12 Health Care Stocks Moving In Wednesday's Intraday Session

  • Press releaseGlobe Newswire

    Traws Pharma Announces Up to $60 Million Private Placement Financing

  • News

    12 Health Care Stocks Moving In Friday's After-Market Session

  • News

    12 Health Care Stocks Moving In Wednesday's After-Market Session

  • News

    12 Health Care Stocks Moving In Thursday's Intraday Session

  • NewsVandana Singh

    Traws Pharma's Oral COVID Drug Shows Comparable Results To Paxlovid

  • News

    12 Health Care Stocks Moving In Friday's Intraday Session

  • Press releasePRNewswire

    ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials

  • Press releasePRNewswire

    Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.

  • News

    12 Health Care Stocks Moving In Friday's Pre-Market Session

  • News

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • NewsAvi Kapoor

    Dow Gains Over 100 Points; US Job Openings Increase In April

  • NewsAvi Kapoor

    US Stocks Mixed; Dollar General Posts Upbeat Earnings

  • Press releasePRNewswire

    Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu

  • News

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • Press releasePRNewswire

    Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program

  • NewsAvi Kapoor

    Nasdaq Down Over 100 Points; US Pending Home Sales Increase In November

  • NewsAvi Kapoor

    Crude Oil Gains 1%; Chicago PMI Falls In December

  • NewsAvi Kapoor

    US Stocks Open Lower; Dow Tumbles 600 Points

  • Press releasePRNewswire

    Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to Approval

  • NewsAvi Kapoor

    Gold Moves Lower, Rumble Shares Jump

  • NewsAvi Kapoor

    Nasdaq Surges Over 100 Points, US Durable Goods Orders Decline In November

  • NewsLekha Gupta

    Traws Pharma Stock Rockets On Promising H5N1 Bird Flu Treatment Results

  • NewsAvi Kapoor

    US Stocks Mixed, Dow Tumbles 150 Points

  • News

    Market-Moving News for December 23rd

  • Press releasePRNewswire

    Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.